Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nanologica AB ( (SE:NICA) ).
Nanologica AB reported a significant increase in net sales for Q3 2025, reaching SEK 2,843 thousand, compared to SEK 611 thousand in the previous year. The company also reduced its operating loss and received several orders for its NLAB Saga® product, including a notable entry into the insulin market with a Chinese manufacturer, indicating a positive shift in market engagement and potential growth opportunities.
The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB operates in the biotechnology industry, focusing on the development and production of silica-based purification media, notably the NLAB Saga® product line. The company targets markets such as pharmaceuticals, with recent engagements in the insulin sector.
Average Trading Volume: 135,555
Technical Sentiment Signal: Sell
Current Market Cap: SEK118M
See more data about NICA stock on TipRanks’ Stock Analysis page.